Bio-Techne Bio-Techne is a company that provides researchers in life science and clinical diagnostics with reagent instruments, custom manufacturing, and testing services. | Humanigen Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science. | |||
Founding Date | Founding Date 1998 | Founding Date 2002 | Founding Date 1981 | Founding Date 2000 |
Type | Type Public | Type Private | Type Public | Type Public |
Tags | ||||
Locations | Locations San Diego, US HQ Beijing, CN Koblenz, DE Bunkyo City, JP Amsterdam, NL London, GB | Locations Minneapolis, US HQ Toronto, CA Praha, CZ Copenhagen, DK Noyal Châtillon Sur Seiche, FR Noyal Châtillon Sur Seiche, FR Planegg, DE see more | Locations Burlingame, US HQ Dublin, IE London, GB Kansas City, US | |
Employees | Employees 1,49229% increase | Employees 6691% increase | Employees 3,0502% increase | Employees 233% decrease |
Valuation ($) | Valuation ($) 5.5 b | Valuation ($) N/A | Valuation ($) 11.6 b | Valuation ($) 4.3 m |
Financial | ||||
Revenue (est.) | Revenue (est.) £361.7m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) $1.2b (FY, 2024) | Revenue (est.) $2.5m (FY, 2022) |
Cost of goods | Cost of goods £37.3m (FY, 2022) | Cost of goods N/A | Cost of goods $389.3m (FY, 2024) | Cost of goods N/A |
Gross profit | Gross profit £324.4m (FY, 2022) | Gross profit N/A | Gross profit $769.7m (FY, 2024) | Gross profit N/A |
Net income | Net income (£8.5m) (FY, 2022) | Net income N/A | Net income $168.1m (FY, 2024) | Net income ($70.7m) (FY, 2022) |
Operating ⚠ | ||||
Patent Applications | Patent Applications N/A | Patent Applications N/A | Patent Applications 270 (FY, 2022) | Patent Applications 17 (FY, 2017) |
Products | Products 130 k (FY, 2020) | Products N/A | Products 350 (FY, 2021) | Products N/A |
Funding | ||||
Total funding raised | Total funding raised $ 78.8m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 131.7m |